Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT
There is a paucity of information on how to select the most appropriate unrelated donor (UD)
in hematopoietic stem cell transplantation (HSCT) using posttransplant cyclophosphamide …
in hematopoietic stem cell transplantation (HSCT) using posttransplant cyclophosphamide …
[HTML][HTML] Efficacy of sars-cov-2 vaccine doses in allogeneic hemopoietic stem cell recipients: A systematic review and meta-analysis
Objective: Recipients of allogeneic hematopoietic cell transplantation (alloHCT) are at
increased risk of morbidity and mortality due to COVID-19. Immune responses to SARS-CoV …
increased risk of morbidity and mortality due to COVID-19. Immune responses to SARS-CoV …
Optimizing Access to Unrelated Donors in Canada: Re-Examining the Importance of Donor Factors on Outcomes Following Hematopoietic Cell Transplantation
HLA-matched allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for
many patients. Unrelated HLA-matched donors are the most frequently used donor for HCT …
many patients. Unrelated HLA-matched donors are the most frequently used donor for HCT …
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide
An increasing number of older patients with acute myeloid leukemia (AML) are offered an
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Normally, older patients …
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Normally, older patients …
Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis
J Ramdial, P Kebriaei, RE Champlin, U Popat… - Leukemia, 2024 - nature.com
As donor age is a significant predictor of hematopoietic cell transplantation (HCT) outcomes
[1, 2], a common clinical dilemma for patients with both an HLA-matched related and an …
[1, 2], a common clinical dilemma for patients with both an HLA-matched related and an …
Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation
WB Fingrut, E Davis, A Archer, S Brown… - Blood …, 2024 - ashpublications.org
Despite the global unrelated donor (URD) registry size, the degree to which URD availability
is a transplant barrier is not established. We evaluated the availability of 3,843 URDs …
is a transplant barrier is not established. We evaluated the availability of 3,843 URDs …
PTCy vs CNI–based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT
J Montoro, M Ngoya, A Kulagin, S Giebel… - Blood …, 2024 - ashpublications.org
Studies comparing the efficacy of posttransplant cyclophosphamide (PTCy) to conventional
calcineurin inhibitor (CNI)–based graft-versus-host disease (GVHD) prophylaxis regimens in …
calcineurin inhibitor (CNI)–based graft-versus-host disease (GVHD) prophylaxis regimens in …
Haploidentical versus HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations
RS Mehta, JL Ramdial, P Kebriaei… - Blood …, 2024 - ashpublications.org
HLA-matched sibling donors (MSDs) are preferred for hematopoietic cell transplantation
(HCT). However, the use of alternative donors, especially haploidentical, is increasing, as is …
(HCT). However, the use of alternative donors, especially haploidentical, is increasing, as is …
Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort
MB Hammami, JA Verceles, M Goldfinger… - … and Cellular Therapy, 2024 - Elsevier
Recent advances in graft-versus-host disease (GVHD) prophylaxis including post-transplant
cyclophosphamide (PTCy) and abatacept have significantly improved outcomes following …
cyclophosphamide (PTCy) and abatacept have significantly improved outcomes following …
A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor …
M Nishijima, K Ido, Y Okayama, H Okamura… - International Journal of …, 2024 - Springer
Acute lymphoblastic leukemia (ALL) relapsed after allogeneic hematopoietic cell
transplantation (allo-HCT) has a catastrophic prognosis. Blinatumomab, a CD3/CD19 …
transplantation (allo-HCT) has a catastrophic prognosis. Blinatumomab, a CD3/CD19 …